The aim of the study was to evaluate the clinical efficacy of insulin glargine 300 U/ml (Gla-300) in the treatment of patients with type 2 diabetes (DM2) insufficiently compensated by basal insulin in the conditions of routine clinical practice in the Czech Republic (TOPAZ study).